Illumina stock

ILMN · NASDAQ · USD

Compare Illumina
$199.75Change from previous close: −3.51%Absolute change: −$7.26

Close · November 16, 2026

Price history

+66.35% over the period

1 year: from $120.08 (November 17, 2025) to $199.75 (November 16, 2026), +66.35%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026$199.75
October 30, 2026$235.99
September 30, 2026$273.68
August 31, 2026$213.63
July 31, 2026$205.10
June 30, 2026$175.83
May 29, 2026$162.96
April 30, 2026$126.74
March 31, 2026$123.26
February 27, 2026$134.46
January 30, 2026$144.81
December 31, 2025$131.16
November 28, 2025$131.45
November 17, 2025$120.08

At a glance

  • The company

    Provide sequencing and array-based solutions for genetic and genomic analysis, serving research centers, academic institutions, hospitals and diagnostic laboratories

  • Latest results

    Quarter to September 30, 2026 · EPS $1.44 (estimate $1.36)

TickerLandia's take on Illumina

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$112.65
52-wk high$309.35

−35.43% from the 52-week high

Analysts · 21 analysts

Average target$261.45+30.89% vs. price

Buy 10 · Hold 7 · Sell 4 · Buy

TickerLandia Fingerprint: Illumina

Compared with similar companies: very low earnings stability and very strong momentum.

Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Illumina is cheaper than in the past and in line with similar companies

On the latest fiscal year's earnings (2025), Illumina's P/E today is 36.7, below the median of its last 7 fiscal years (48.0; between 24.8 and 80.9 from 2016 to 2025). Illumina's P/E (trailing 12 months): 36.1, in line with the median of a group of 9 similar companies (36.1).

P/E compared with its history

Compared with 9 similar companies

Illumina's metrics compared with similar companies
MetricIlluminaPosition in the groupBand
P/E (trailing 12 months)36.1Middle
Forward P/E33.5Middle
Operating margin19.1%Middle
ROE32.4%Middle
Debt/equity0.74Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Illumina. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$1.16B

Latest quarter · Q2 2026

Net income

$207M

Latest quarter · Q2 2026

Quarterly net margin

17.9%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$31.3B
P/E
36.1
EPS
$5.74
Volume
1.23M
Daily trading
€488.21M

How Illumina is changing

All results
  • Revenue grew 6.0% a year on average over the last 5 years

  • Operating margin rose from −91.2% to 18.6%

  • Shares outstanding up 5.4% in 5 years

Returns

Illumina returns with dividends

$1,000 invested in Illumina 5 years ago, on November 16, 2021, would be worth $543 today: −45.75% in total, −11.51% per year. This is the price return only: dividends are excluded.

PeriodIlluminaS&P 500$1,000 becomes
1 month−23.92%−3.12%$761
6 months+40.14%+2.07%$1,401
Year to date+52.29%+10.46%$1,523
1 year+66.35%+13.33%$1,663
3 years+121.79%+67.73%$2,218
5 years−45.75%+60.86%$543
10 years+52.25%+247.35%$1,523

Over the last 6 months it has done better than 78% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment

The chart in detail

Illumina: technical analysis

Illumina shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 60.9% below its all-time closing high ($510.54, August 16, 2021).

Trend
No clear trend
RSI (14 sessions)
33
Between 30 and 70
vs 200-session average
+11.10%

Support and resistance

Price areas where Illumina has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last price$199.75
  3. Support$198.33−0.71%2 touches, last on September 11, 2026
  4. Support$178.05−10.86%2 touches, last on July 21, 2026
  5. Support$154.05−22.88%5 touches, last on June 17, 2026

Volatility and risk

Over the last year it has moved roughly in line with the S&P 500.

Beta (1 year) vs S&P 500
1.10
Volatility (60 sessions, annualised)
69.4%
Largest fall in the last year
−31.99%

In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Illumina: seasonality

Average monthly price change over 27 years

+9.2%Jan−4.5%Feb−0.1%Mar+1.7%Apr+4.9%May+4.5%Jun+2.3%Jul−0.3%Aug+0.9%Sep+2.3%Oct+1.1%Nov+2.9%Dec

Over the last 27 years, the strongest month for Illumina has been January: +9.22% on average, positive in 18 years out of 26. The weakest has been February: −4.50% on average, positive in 9 years out of 26. November, the current month, has been positive in 15 years out of 26 (+1.13% on average).

Show chart data
MonthAverageMedianPositive years
January+9.22%+5.84%18 of 26
February−4.50%−2.10%9 of 26
March−0.10%+1.45%14 of 26
April+1.72%+0.86%16 of 26
May+4.85%+1.15%15 of 26
June+4.48%+4.63%19 of 26
July+2.26%+3.09%18 of 26
August−0.33%−2.48%12 of 27
September+0.88%−0.75%13 of 27
October+2.32%+3.01%15 of 27
November+1.13%+2.04%15 of 26
December+2.92%+3.10%16 of 26

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Illumina and its competitors

The Americas generate the largest share of revenue, 55.4% of the total in the fiscal year ended December 2025, followed by Europe at 29.1%, Asia Pacific, the Middle East and Africa at 9.9%, and China at 5.6%. The company develops sequencing and array platforms for genomic analysis, with instruments and consumables such as reagents, flow cells and library preparation kits. Its whole-genome and targeted resequencing kits cover entire genomes, exomes, specific genes and RNA regions.

Headquarters
San Diego, United States
Employees
8,600
Founded
1998
Chief executive
Jacob Thaysen
Illumina and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
IlluminaILMN$31.3B19.1%36.1+40.14%
Labcorp HoldingsLH$30.08B11.2%30.4+48.09%
Quest DiagnosticsDGX$28.56B14.9%25.9+40.23%
Mettler-Toledo InternationalMTD$34.59B27.8%37.7+67.76%
IQVIA HoldingsIQV$43.36B13.9%32.0+56.42%
NateraNTRA$46.27B-8.5%—+56.81%

Same industry or related industries, similar size. Compare Illumina with its competitors · Full profile